Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Sep;53(9):1139-1148.
doi: 10.1038/s41409-018-0153-1. Epub 2018 Mar 14.

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report

Jakob R Passweg  1 , Helen Baldomero  2 , Peter Bader  3 , Grzegorz W Basak  4 , Chiara Bonini  5 , Rafael Duarte  6 , Carlo Dufour  7 , Nicolaus Kröger  8 , Jürgen Kuball  9 , Arjan Lankester  10 , Silvia Montoto  11 , Arnon Nagler  12 , John A Snowden  13 , Jan Styczynski  14 , Mohamad Mohty  15 ; European Society for Blood and Marrow Transplantation (EBMT)
Affiliations
Multicenter Study

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report

Jakob R Passweg et al. Bone Marrow Transplant. 2018 Sep.

Abstract

Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency for continued activity in this field with 43,636 HCT in 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers in 49 countries in 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid malignancies 25,618 (65%; 20% allogeneic), solid tumors 1516 (4%; 2% allogeneic), and non-malignant disorders 2459 (6%; 85% allogeneic). There was a remarkable leveling off in the use of unrelated donor HCT being replaced by haploidentical HCT. Continued growth in allogeneic HCT for marrow failure, AML, and MPN was seen, whereas MDS appears stable. Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma. Trends in CLL are not clear, with recent increases after a decrease in activity. In autologous HCT, the use in myeloma continues to expand but is stable in Hodgkin lymphoma. There is a notable increase in autologous HCT for autoimmune disease. These data reflect the most recent advances in the field, in which some trends and changes are likely to be related to development of non-transplant technologies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Relative proportion of disease indications for HCT in Europe in 2016. a Allogeneic HCT. b Autologous HCT
Fig. 2
Fig. 2
Trend in the absolute numbers of HCT in Europe 1990–2016. a Trend in allogeneic and autologous HCT. b Changes in donor choice. c Trend in cord blood HCT
Fig. 3
Fig. 3
Major trends in disease indication in Europe 1990–2016. a Allogeneic HCT for CML in early and late stage. b Allogeneic HCT for MDS and MPN. c Allogeneic HCT for BMF. d Allogeneic HCT for lymphoproliferative disorders. e Autologous HCT for lymphoproliferative disorders. f Autologous HCT for auto immune disease
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. doi: 10.1056/NEJMra052638. - DOI - PubMed
    1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472–5. doi: 10.1056/NEJMp078166. - DOI - PubMed
    1. Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037–56. doi: 10.1038/bmt.2015.6. - DOI - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. doi: 10.1001/jama.2010.491. - DOI - PMC - PubMed
    1. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–e100. doi: 10.1016/S2352-3026(15)00028-9. - DOI - PubMed

Publication types

MeSH terms